NCT04075747 - A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 2, 2019

Primary Completion Date

February 7, 2022

Study Completion Date

September 12, 2023

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

CPX-351

Up to 2 induction and 2 consolidation courses will be offered

DRUG

Venetoclax

Will be administered over specified duration during induction and consolidation courses

DRUG

Midostaurin

Will be administered over specified duration during induction and consolidation courses

DRUG

Enasidenib

Will be administered over specified duration during induction and consolidation courses

Trial Locations (10)

Johns Hopkins University, Baltimore

Duke University, Durham

Georgia Cancer Center at Augusta University, Augusta

Vanderbilt Ingram Cancer Center, Nashville

University of Kansas Cancer Center, Fairway

University of Nebraska Medical Center, Omaha

City of Hope National Medical Center, Duarte

Stanford University School of Medicine- Standford Cancer Institute, Palo Alto

Massachusetts General Hospital, Boston

Hackensack University Medical Center, Hackensack